Literature DB >> 21519188

Filovirus vaccines.

Steven B Bradfute1, John M Dye, Sina Bavari.   

Abstract

Filoviruses can cause severe and often fatal hemorrhagic fever in humans and non-human primates (NHPs). Although there are currently no clinically proven treatments for filovirus disease, much progress has been made in recent years in the discovery of therapeutics and vaccines against these viruses. A variety of vaccine platforms have been shown to be effective against filovirus infection. This review summarizes the literature in this field, focusing on vaccines that have been shown to protect NHPs from infection. Furthermore, the uses of rodent models in vaccine development, as well as correlates of immunity, are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519188      PMCID: PMC3219077          DOI: 10.4161/hv.7.6.15398

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  93 in total

1.  The pathology of experimental Ebola virus infection in monkeys.

Authors:  A Baskerville; E T Bowen; G S Platt; L B McArdell; D I Simpson
Journal:  J Pathol       Date:  1978-07       Impact factor: 7.996

2.  The aetiology of an unknown human infection transmitted by monkeys (preliminary communication).

Authors:  R Siegert; H L Shu; H L Slenczka; D Peters; G Müller
Journal:  Ger Med Mon       Date:  1968-01

3.  Marburg agent disease: in monkeys.

Authors:  D I Simpson
Journal:  Trans R Soc Trop Med Hyg       Date:  1969       Impact factor: 2.184

4.  Ebola virus virulence for newborn mice.

Authors:  G van der Groen; W Jacob; S R Pattyn
Journal:  J Med Virol       Date:  1979       Impact factor: 2.327

5.  Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team.

Authors: 
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

6.  Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire.

Authors:  S Pattyn; G van der Groen; W Jacob; P Piot; G Courteille
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

7.  Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent.

Authors:  E T Bowen; G Lloyd; W J Harris; G S Platt; A Baskerville; E E Vella
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

8.  [A strain of "Marburg virus" (Rhabdovirus simiae) pathogenic to mice].

Authors:  H Hofmann; C Kunz
Journal:  Arch Gesamte Virusforsch       Date:  1970

9.  Ebola haemorrhagic fever: experimental infection of monkeys.

Authors:  E T Bowen; G S Platt; D I Simpson; L B McArdell; R T Raymond
Journal:  Trans R Soc Trop Med Hyg       Date:  1978       Impact factor: 2.184

10.  Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection.

Authors:  Kelly L Warfield; Dana L Swenson; Diane L Negley; Alan L Schmaljohn; M Javad Aman; Sina Bavari
Journal:  Vaccine       Date:  2004-09-03       Impact factor: 3.641

View more
  19 in total

Review 1.  Characterization of a putative filovirus vaccine: virus-like particles.

Authors:  Karen A O Martins; Travis K Warren; Sina Bavari
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

2.  Generation and characterization of protective antibodies to Marburg virus.

Authors:  Jeffrey W Froude; Thibaut Pelat; Sebastian Miethe; Samantha E Zak; Anna Z Wec; Kartik Chandran; Jennifer Mary Brannan; Russell R Bakken; Michael Hust; Philippe Thullier; John M Dye
Journal:  MAbs       Date:  2017-03-13       Impact factor: 5.857

3.  A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.

Authors:  Amy B Papaneri; Christoph Wirblich; Jennifer A Cann; Kurt Cooper; Peter B Jahrling; Matthias J Schnell; Joseph E Blaney
Journal:  Virology       Date:  2012-08-11       Impact factor: 3.616

4.  Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.

Authors:  Amy B Papaneri; Christoph Wirblich; Kurt Cooper; Peter B Jahrling; Matthias J Schnell; Joseph E Blaney
Journal:  Vaccine       Date:  2012-08-08       Impact factor: 3.641

5.  A substitution in the transmembrane region of the glycoprotein leads to an unstable attenuation of Machupo virus.

Authors:  Michael Patterson; Takaaki Koma; Alexey Seregin; Cheng Huang; Milagros Miller; Jennifer Smith; Nadezhda Yun; Jeanon Smith; Slobodan Paessler
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

Review 6.  Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?

Authors:  Michelle Meyer; Delphine C Malherbe; Alexander Bukreyev
Journal:  Trends Microbiol       Date:  2018-09-07       Impact factor: 17.079

7.  Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species.

Authors:  Roland Zahn; Gert Gillisen; Anna Roos; Marina Koning; Esmeralda van der Helm; Dirk Spek; Mo Weijtens; Maria Grazia Pau; Katarina Radošević; Gerrit Jan Weverling; Jerome Custers; Jort Vellinga; Hanneke Schuitemaker; Jaap Goudsmit; Ariane Rodríguez
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240

Review 8.  Mouse models for filovirus infections.

Authors:  Steven B Bradfute; Kelly L Warfield; Mike Bray
Journal:  Viruses       Date:  2012-09-07       Impact factor: 5.048

9.  Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.

Authors:  Joseph E Blaney; Andrea Marzi; Mallory Willet; Amy B Papaneri; Christoph Wirblich; Friederike Feldmann; Michael Holbrook; Peter Jahrling; Heinz Feldmann; Matthias J Schnell
Journal:  PLoS Pathog       Date:  2013-05-30       Impact factor: 6.823

Review 10.  Potential vaccines and post-exposure treatments for filovirus infections.

Authors:  Brian M Friedrich; John C Trefry; Julia E Biggins; Lisa E Hensley; Anna N Honko; Darci R Smith; Gene G Olinger
Journal:  Viruses       Date:  2012-09-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.